S G I Pharmacuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.55 M
- Company Age 31 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 1176.18%
- Profit Growth 587.18%
- Ebitda 230.83%
- Net Worth 7.48%
- Total Assets 7572.66%
About S G I Pharmacuticals
S G I Pharmacuticals Limited (SGIPL) is a Public Limited Indian Non-Government Company incorporated in India on 15 June 1993 and has a history of 31 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.55 M, as per Ministry of Corporate Affairs (MCA) records.
Adish Jain, Raj Jain, and Charanjeet Singh serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24239DL1993PLC054060
- Company No.
054060
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Jun 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at S G I Pharmacuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Adish Jain  | Director | 17-Jan-2017 | Current |
| Raj Jain | Director | 10-Jan-2017 | Current |
| Charanjeet Singh | Director | 24-Jul-2023 | Current |
Financial Performance of S G I Pharmacuticals.
S G I Pharmacuticals Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1176.18% increase. The company also saw a substantial improvement in profitability, with a 587.18% increase in profit. The company's net worth moved up by a moderate rise of 7.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S G I Pharmacuticals?
In 2020, S G I Pharmacuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Usky Logistics Private LimitedAdish Jain and Charanjeet Singh are mutual person
Jetset Shipping Private LimitedAdish Jain and Charanjeet Singh are mutual person
- Pick A Parcel Private Limited
Adish Jain and Charanjeet Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at S G I Pharmacuticals?
Unlock and access historical data on people associated with S G I Pharmacuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S G I Pharmacuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S G I Pharmacuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
